Phase II Study of the FGFR Inhibitor Pemigatinib for Previously Treated Metastatic CRC With FGF/FGFR Alterations

Source: CCO Independent Conference Highlights of the 2023 ASCO Gastrointestinal Cancers Symposium*
Download Slideset
January 19-21, 2023; San Fransico, California
In this phase II study, no responses were seen with pemigatinib in the 14 enrolled patients with previously treated mCRC with FGF/FGFR gene mutations or amplifications.
Format: Microsoft PowerPoint (.ppt)
File Size: 124 KB
Released: January 30, 2023

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Incyte Corporation
Merck Sharp & Dohme Corp.
Seagen Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings